Drug Safety Information for SANDOSTATIN (Octreotide acetate)
Safety-related Labeling Changes for SANDOSTATIN (OCTREOTIDE ACETATE) Rx Drug: FDA Link
Safety-related Labeling Changes for SANDOSTATIN LAR (OCTREOTIDE ACETATE) Rx Drug: FDA Link
Adverse Drug Reactions for SANDOSTATIN* (Octreotide acetate)
These charts and graphs are based on reports received through the FDA Adverse Event Reporting System (FAERS) program (see below).
Top 20 Adverse Effects Associated with SANDOSTATIN
(reported in FDA Medwatch/FAERS Reports)
Side Effect | # of FDA Reports | |
---|---|---|
1 | Death | 1785 |
2 | Diarrhoea | 1327 |
3 | Fatigue | 839 |
4 | Neoplasm malignant | 804 |
5 | Nausea | 783 |
6 | Asthenia | 701 |
7 | Abdominal pain | 664 |
8 | Malaise | 662 |
9 | Weight decreased | 629 |
10 | Blood pressure increased | 593 |
11 | Pain* | 584 |
12 | Vomiting | 583 |
13 | Dyspnoea | 525 |
14 | Headache | 441 |
15 | Dizziness | 428 |
16 | Blood pressure systolic increased | 397 |
17 | Fall | 395 |
18 | Injection site pain | 392 |
19 | Decreased appetite | 384 |
20 | Pyrexia | 361 |
* This side effect also appears in "Top 10 Side Effects of SANDOSTATIN " in the drug's Review Summary based on AskaPatient reviews.
Top 10 Reasons for Taking SANDOSTATIN
(associated with FDA Medwatch/FAERS Reports)
Reason | # of FDA Reports | |
---|---|---|
1 | Acromegaly | 7788 |
2 | Carcinoid tumour | 6476 |
3 | Neuroendocrine tumour | 6153 |
4 | Carcinoid syndrome | 3429 |
5 | Pancreatic neuroendocrine tumour | 2037 |
6 | Metastatic carcinoid tumour | 1552 |
7 | Product used for unknown indication | 1129 |
8 | Neuroendocrine carcinoma | 1085 |
9 | Diarrhoea | 652 |
10 | Off label use | 498 |
*Also a top-10 reason in AskaPatient Review Summary.
Types of Adverse Events for SANDOSTATIN
Total Reports Filed with FDA: 51931
Number of FDA Adverse Event Reports by Patient Age for SANDOSTATIN
Total Reports Filed with FDA: 51931*
* Reports for drugs with the same active ingredients have been aggregated in this analysis: Octreotide acetate (Octreotide, Sandostatin lar, Sandostatin, Octreotide acetate)
Charts are based on 51931 reports filed with the FDA between 2004 and June 2015.
Adverse Event Reports are submitted to the FDA by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers), health care providers such as doctors (voluntary reporting), and by patients themselves (voluntary reporting). More Information on FDA MedWatch (FDA Safety Information and Adverse Event Reporting Program)Voluntary reporting takes place under the FDA's MedWatch program, where health care professionals and consumers submit reports to FDA when they find a problem with a drug, medical device, biologic, or other FDA-regulated product. An adverse event is any undesirable experience or extreme side effect associated with the use of a medical product. Adverse events include: death, life threatening event, hospitalization, disability or permanent damage, congenital anomaly or birth defect, medical product use requiring a surgical or other intervention, or other serious medical situation believed to be caused by the drug.
Click to go back to search results and SANDOSTATIN Reviews and Review Summary .
Historical Analytics of FDA Adverse Event Reports Provided by Druginformer.com. FDA Drug Safety Information, including safety-related labeling updates, required post-approval safety studies, risk evaluation management strategies (REMS), alerts, and recalls are compiled by AskaPatient.com from the U.S. Food and Drug Administration.